Skip to main content

Table 2 Clinicopathologic parameters and the expression of VEGF as predictors of response to neoadjuvant chemotherapy in patients with bulky cervical carcinoma

From: Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy

    Pathologic responder Nonresponder   
Characteristics No. of patients RR CR (n = 4) OPR a (n = 4) (n = 21) P b P c
Age, years       0.16  
   Median    58 47 46   
   Range    38 – 60 34 – 60 33 – 70   
Cervical tumor size (cm)       0.07 0.22
   Median    3.8 3.5 5.0   
   Range    3.2 – 6.0 3.0 – 5.6 3.7 – 7.1   
Clinical node involvement       0.98 0.22
   Yes 11 27.3% 2 1 8   
   No 18 27.8% 2 3 13   
Stage       0.67 0.54
   IB2 20 30.0% 2 4 14   
   IIA 9 22.2% 2 0 7   
SCC Ag level       0.47 0.36
   ≥5 ng/ml 14 21.4% 1 2 11   
   < 5 ng/ml 15 33.3% 3 2 10   
VEGF expression       0.009 0.032
   Negative 14 50.0% 3 4 7   
   Positive 15 6.7% 1 0 14   
  1. aResidual tumor but only with less than 3 mm stromal invasion
  2. bRank sum test or Chi-square test/Fisher's exact test
  3. cLogistic regression analysis with stage, tumor size, SCC-Ag level, and lymph node involvement as a covariate.
  4. RR, pathologic response rate; CR, complete response; OPR, optimal pathologic response